Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management: An Extension Study
NCT ID: NCT05433337
Last Updated: 2024-06-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2022-06-08
2024-03-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management
NCT05243511
"REACT-FM-EXT": Real-World Evidence From Smartphone-Based Acceptance and Commitment Therapy in Fibromyalgia: An Extension Study
NCT05149222
"SMART-FM": Smart-Phone Based Digital Therapeutic for Management of Fibromyalgia
NCT05005351
"REACT-FM" Real-World Evidence From Smartphone-Based Acceptance and Commitment Therapy in Fibromyalgia
NCT05011162
Healing Through Affective Self-Awareness in Fibromyalgia: a Randomized Controlled Trial
NCT00437411
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Digital Acceptance and Commitment Therapy (ACT) Arm
Digital ACT
Study participants will continue to receive Digital Acceptance and Commitment Therapy in addition to their standard care for fibromyalgia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Digital ACT
Study participants will continue to receive Digital Acceptance and Commitment Therapy in addition to their standard care for fibromyalgia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant is willing and able to comply with all protocol-specified requirements
Exclusion Criteria
* Severe depression at the final visit of the PROSPER-FM study (measured by BDI-II)
* Increased risk of suicide on the basis of the investigator's judgment or the Columbia-Suicide Severity Rating Scale ("C-SSRS") at the final visit of the PROSPER-FM study
22 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Swing Therapeutics, Inc.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brian Keefe, MD
Role: PRINCIPAL_INVESTIGATOR
Swing Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Swing Therapeutics
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Swing Therapeutics Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Swing-005-EXT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.